Rosuvastatin and atorvastatin were associated with greater LDL-cholesterol reduction compared with simvastatin in primary health care. Combination therapy with ezetimibe significantly increased the likelihood of achieving therapeutic LDL targets.
Alidema et al. (Mon,) studied this question.